A Phase 4 interventional study of Lacrifill and Saline in Dry Eye, Ocular Surface Disease and Cataract Surgery, sponsored by Eye Research Associates, LLC. Recruiting at 2 sites in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-09-25.
Sponsored by Eye Research Associates, LLC · Phase 4, Interventional, and Prevention
Among 542 studies in Dry Eye Syndromes with a site in United States — 51 open to participants now, 61 under way, 3 of them phase 3. Dry Eye Syndromes · United States.
Among the 542 studies in Dry Eye Syndromes with a site in United States, this one is the 308th largest by planned enrollment of the 472 interventional ones that give a count, is one of 34 that started in 2026, is one of 116 in phase 4, reaches primary completion later than 25 of the 60 other live ones, and was the 534th registered.
1,366 studies on the registry are indexed under Dry Eye Syndromes; 207 are open to participants now.
Browse Dry Eye Syndromes studies →51 of the 542 studies in Dry Eye Syndromes with a site in United States are open now. Recruiting first, the newest first:
Scott & Christie and Associates, PC · Sites in United States
Bausch & Lomb Incorporated · Sites in United States
Alcon Research · Sites in United States
Cleveland Eye Clinic · Sites in United States
University of Rochester · Sites in United States
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 116 Dry Eye Syndromes studies recruiting now, 73 (63%) set no upper age limit and 24 (21%) stop at 75 or younger; 7 take children under 18; 29 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
542 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 36 · Phase 2 132 · Phase 3 95 · Phase 4 116
First in 1997; this study’s year is marked. 34 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 40 is below the median of 60 across 1,129 interventional studies indexed under Dry Eye Syndromes.
Median enrollment 60 across the 472 interventional studies, 80 across the 63 observational. Of the 439 that completed or were terminated, 232 (53%) have results posted.
This tab as a report to print or save as PDF → With an account.
329 of 542 have an industry lead sponsor. The 10 most frequent:
Eye Research Associates, LLC is the lead sponsor of 2 studies on the registry; 2 are open to participants now.
Eye Research Associates, LLC has 2 studies filed under Dry Eye Syndromes — fewer than ten, so there is no comparison to draw.
29 of the studies in Dry Eye Syndromes with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07548632Phase 3OculisA Clinical Study Evaluating Licaminlimab for Dry Eye Disease | 2026-12 |
| NCT07768735Alcon ResearchUNITY DX Cornea Study | 2026-11 |
| NCT07281950Center for Sight Las VegasInvestigator Initiated Trial Using Dry Eye Surveys to Evaluate and Better Understand FDA Approved Acoltremon Treatment for Dry Eye Disease in Real World Treatment Settings (DESERT) | 2026-11-30 |
| NCT07566975Neuro-Ophthalmology of TexasReal-World Assessment of VEVYE® for Short-Term Symptom and Sign Improvement of Dry Eye Disease in a Neuro-Ophthalmology Clinic: A 6-Month Prospective Observational Study | 2026-11-30 |
| NCT07928986Cleveland Eye ClinicA Multi Center Evaluation of TearCare on Surgical Measurements Before Cataract Surgery | 2026-12 |
Among the 542 studies in Dry Eye Syndromes with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Dry Eye Disease is defined as "a multifactorial disease of the tears and ocular surface that results in symptoms of discomfort, visual disturbance, and tear film instability with potential damage to the ocular surface. It is accompanied by increased osmolarity of the tear film and inflammation of the ocular surface.' 'By the The Tear Film and Ocular Surface Society. Despite there being a number of factors that impact DED however one factor that has been considered likely is that of a complication from ocular surgery itself. Which can cause both corneal nerve, and ocular surface damage. Therefore this study aims to determine how Lacrfill performs in preventing post-operative dry eye symptoms in those who have recently had unilateral cataract surgery.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Qualifying subjects will be treated with Lacrifill via the manufacturer's instructions
Drug: Lacrifill
Qualifying subjects will be treated with saline via the manufacturer's instructions
Drug: Saline
Participants will receive Lacrifill achemically crosslinked, particulate hyaluronic acid (HA) hydrogel intracanalicular occlusion device that is intended to occlude tear drainage
Participants will be provided with a saline eye drop which is standard of care for those recovering from cataract surgery, and other complications that could cause symptoms related to Dry Eye Disease.
OSDI Scores at the 1-month post-operative visit compared to pre-treatment (0-100 scale)
Ocular Surface Disease Index scores will be determined on a scale with higher scores meaning more discomfort.
Time frame: 1-month post operative compared to pre-treatment
• OSDI Scores at the 3-month post-operative visit compared to pre-treatment (0-100 scale).
Ocular Surface Disease Index scores will be determined on a scale with higher scores meaning more discomfort.
Time frame: pre-treatment as compared to 3 months post operative.
Eye Dryness visual analog scale (VAS) Scores 1 month post operative
The Eye Dryness visual analog scale VAS will be conducted 1 month post operative with higher scores indicating more discomfort. Scale 0-100 with score 0 representing No Symptoms and Score 100 representing Severe Symptoms.
Time frame: 1 month post operative as compared to pre-treatment.
Eye Dryness visual analog scale (VAS) Scores 3 month post operative
The Eye Dryness visual analog scale VAS will be conducted 3 month post operative with higher scores indicating more discomfort. Scale 0-100 with score 0 representing No Symptoms and Score 100 representing Severe Symptoms.
Time frame: 3 month post operative as compared to pre-treatment.
Started Sep 2026 (actual). Primary completion is estimated for Dec 2026, 3 months after the start.
Of 84 non-industry phase 4 interventional studies under Dry Eye Syndromes, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 28. This study's planned 3 months is below that.
Counting every sponsor, half of 112 studies reached it within 12 months; a quarter within 5 and three quarters within 23.
Start moved once since we started tracking on Sep 25, 2026: Aug 2026 → Sep 2026, on Sep 25, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Eye Research Associates, LLC